Oramed, an Israeli developer of oral drug delivery systems, said on Thursday a mid-stage trial for its oral insulin capsule for the treatment of type 2 diabetes met all primary and secondary endpoints. During the Phase 2a trial, conducted under a U.S. Food and Drug Administration new drug protocol, 30 patients with type 2 diabetes took part in an in-patient setting for one week. "We are extremely pleased with the results, which give a solid validation for Oramed's platform technology in general and our oral insulin programme in particular," said Nadav Kidron, Oramed's chief executive.
via Health News Headlines - Yahoo News http://ift.tt/Mk3bjg
No comments:
Post a Comment